Overview

HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial

Status:
Recruiting

Trial end date:
2022-10-01

Target enrollment:
0

Participant gender:
All

Summary

Data regarding hepatocellular carcinoma (HCC) recurrence after directly acting antivirals (DAAs) given for hepatitis C virus treatment are contradictory. Surprisingly, some studies reported that DAAs are accompanied with higher HCC recurrence. But, other studies showed no rise or even decrease in HCC recurrence. Most of these studies were retrospective and some were non-randomized prospective studies. Here investigators aim to perform a randomized controlled trial to study this issue.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Alexandria University

Treatments:

Sofosbuvir
Velpatasvir

Criteria

Inclusion Criteria:

- Child-Pugh A and B subjects with hepatitis C related < 5 cm single or up to 3
hepatocellular carcinomas without any vascular or extrahepatic involvement

Exclusion Criteria:

- Those with positive HBsAg, history of alcohol consumption, patients with other known
causes of chronic liver disease, patients who have received previous DAAs for HCV and
patients who have received previous locoregional treatment for HCC will be excluded.